30 closest matches · ranked by relevance
Alpha-1 Antitrypsin Deficiency (AATD) · Pi*ZZ, Pi*SZ, Pi*Null, Another Rare Phenotype/Genotype Known to be Associated With Either Low or Functionally Impaired AAT Including F or I Mutations · Emphysema or COPD
Primary: Within-individual % Change in Plasma Desmosine/Isodesmosine — 10.0619; 8.5627 % change
Alpha 1-Antitrypsin Deficiency
Primary: Adverse Events Possibly, Probably or Definitely Related to Study Drug — 2; 2; 3; 2 participants
Emphysema · Alpha 1-antitrypsin Deficiency (AATD)
Primary: Subjects With Treatment-Emergent Adverse Events (TEAEs) — 23; 18 participants
Acute Myocardial Infarction
Primary: C Reactive Protein (Area Under the Curve) — 75.9 mg/L
Alpha 1-Antitrypsin Deficiency
Primary: The Progression Rate of Emphysema Determined by Change in 15th Percentile of Lung Density Measured by Annual CT Scan of the Whole Lung — 47.980; 45.477; 45.085; 41.354…
Alpha 1-Antitrypsin Deficiency
Primary: Treatment-emergent Adverse Events (TEAEs) Defined as Any Adverse Event (AE) Occurring During or After the Start of the First Study Drug Infusion. — 38; 26; 17; 5…
Alpha₁-Antitrypsin Deficiency
Primary: AUC(0-7 Days) Based on Antigenic Content — 203.20; 198.38 mg*h/mL
Alpha-1 Antitrypsin Deficiency
Primary: Change From Baseline in the Concentration of Antigenic Alpha-1 Antitrypsin (AAT) in the Lung Epithelial Lining Fluid (ELF) — 4551.023; 13454.772; -27.15 nmol — p=0.0005
Alpha-1 Antitrypsin Deficiency · Emphysema · Chronic Obstructive Pulmonary Disease
Primary: Pulmonary Microvascular Blood Flow, Mean — 36.9; 35.1 mL blood/minute per 100mL lung — p=0.692
Alpha-1 Antitrypsin Deficiency
Primary: Frequency of Grade 3 or 4 Adverse Events — 0; 0; 1 participants
Alpha1-proteinase Inhibitor Deficiency · Emphysema
Primary: Annual Rate of Change in Lung Density — -1.50; -2.12; -1.45; -2.19 g/L per year — p=0.029
Chronic Pancreatitis
Primary: Islet Graft Function — 233; 354 ng/ml*min
Alpha 1-Antitrypsin Deficiency
Primary: Change in Bronchoalveolar Lavage (BAL) Epithelial Lining Fluid (ELF) Alpha1-Proteinase Inhibitor (α1-PI) Level — 0.28 μM — p=0.0195
Alpha1-Antitrypsin Deficiency
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 3 Participants
Alpha1-Antitrypsin Deficiency
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 4 Participants
Graft-Versus-Host Disease (GVHD) Acute on Chronic
Primary: Number (Percentage) of Patients at Each Dosing Cohort Who Experience no Toxicity and in Whom Graft Versus Host Disease (GVHD) is Stable or Improved — 6; 2; 2 Participants
Alpha 1 Antitrypsin Deficiency
Primary: Changes in Inflammatory Biomarkers in Bronchoalveolar Lavage Fluid — 14.3; 8.1; 10.3; 379.9 pg/ml — p=<0.05
Alpha-1 Antitrypsin Deficiency · Emphysema · COPD
Primary: Number of Participants With Abnormal Sequences in SERPINA1 Genes — 6; 0 participants — p=0.054
Alpha 1-Antitrypsin Deficiency
Primary: Alpha-1 MP vs. Prolastin® of Area Under the Curve (AUC) From Day 0 to Day 7 — 155.9; 152.4 mg*h/mL
Graft vs Host Disease
Primary: Percentage of Patients That Respond to Treatment — 65 percentage of patients
Alpha 1-Antitrypsin Deficiency
Primary: Percent Change From Baseline in Total Liver Z-AAT, Insoluble Liver-ZAAT, and Soluble Liver Z-AAT at Week 24: Cohorts 1/1b — -83.07; -79.84; -81.58; -12.91 percent change
Cystic Fibrosis
Primary: Change in Free Elastase in Induced Sputum From Baseline to Week 4 — -7.42; 6.11 ug/mL — p=0.197
HIV Disease
Primary: CD4/CD8 Ratio — 0.44 Ratio
Alpha1-antitrypsin Deficiency
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Potentially Related to Presence of Particle Load in the GLASSIA Solution — 0; 0 Participants
Emphysema · Alpha 1-proteinase Inhibitor Deficiency
Primary: Rate of Change of Adjusted Lung Density — -1.632; -1.352; -1.627; -1.256 g/L per year — p== 0.752
Cystic Fibrosis
Primary: Adverse Events — 100; 80; 60 percentage of participants
Graft-versus-host-disease · GVHD
Primary: Number of High Risk Patients Who Develop Steroid Refractory GVHD — 6 Participants
Alpha 1-Antitrypsin Deficiency
Primary: Percent Change From Baseline in Serum Z-Alpha-1 Antitrypsin (Z-AAT) at Week 16 — -62.17; -85.39; -92.93; 4.64 percentage change — p=< 0.0001
Alpha 1-Antitrypsin Deficiency
Primary: Area Under the Curve/Dose — 0.0822; 0.0920 days*kg/mL
Pulmonary Disease, Chronic Obstructive · Pulmonary Emphysema
Primary: Absolute Change From Baseline at Week 156 in Adjusted Lung Density (ALD) Based on Percentile Density at 15% (PD15) Adjusted for Lung Volume — -0.27; -3.15; -5.04; -4.74…